[go: up one dir, main page]

AU2001258754A1 - Aqueous liquid preparation - Google Patents

Aqueous liquid preparation

Info

Publication number
AU2001258754A1
AU2001258754A1 AU2001258754A AU5875401A AU2001258754A1 AU 2001258754 A1 AU2001258754 A1 AU 2001258754A1 AU 2001258754 A AU2001258754 A AU 2001258754A AU 5875401 A AU5875401 A AU 5875401A AU 2001258754 A1 AU2001258754 A1 AU 2001258754A1
Authority
AU
Australia
Prior art keywords
aqueous liquid
liquid preparation
aqueous solution
acceptable salt
pharmacologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258754A
Inventor
Hisayuki Nakayama
Fukiko Yamasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senju Pharmaceutical Co Ltd
Original Assignee
Senju Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharmaceutical Co Ltd filed Critical Senju Pharmaceutical Co Ltd
Publication of AU2001258754A1 publication Critical patent/AU2001258754A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides an aqueous solution containing pranoprofen or a pharmacologically acceptable salt thereof, and a sulfa drug, and a method for making pranoprofen or a pharmacologically acceptable salt thereof stable to light in an aqueous solution, which includes adding a sulfa drug to the aqueous solution containing pranoprofen or a pharmacologically acceptable salt thereof.
AU2001258754A 2000-05-17 2001-05-16 Aqueous liquid preparation Abandoned AU2001258754A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-145640 2000-05-17
JP2000145640 2000-05-17
PCT/JP2001/004083 WO2001087303A1 (en) 2000-05-17 2001-05-16 Aqueous liquid preparation

Publications (1)

Publication Number Publication Date
AU2001258754A1 true AU2001258754A1 (en) 2001-11-26

Family

ID=18652118

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258754A Abandoned AU2001258754A1 (en) 2000-05-17 2001-05-16 Aqueous liquid preparation

Country Status (10)

Country Link
EP (1) EP1283042B1 (en)
JP (1) JP4754149B2 (en)
KR (1) KR100776579B1 (en)
CN (1) CN1210028C (en)
AT (1) ATE410164T1 (en)
AU (1) AU2001258754A1 (en)
DE (1) DE60136064D1 (en)
ES (1) ES2310550T3 (en)
PT (1) PT1283042E (en)
WO (1) WO2001087303A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5785353B2 (en) * 2004-02-27 2015-09-30 大正製薬株式会社 Ophthalmic agent
JP2005247803A (en) * 2004-03-08 2005-09-15 Zeria Pharmaceut Co Ltd Eye drops and their containers
JP2005247801A (en) * 2004-03-08 2005-09-15 Zeria Pharmaceut Co Ltd Stable eye drops
JP4845405B2 (en) * 2004-03-29 2011-12-28 ロート製薬株式会社 Planoprofen-containing pharmaceutical preparation
JP5623684B2 (en) * 2006-10-13 2014-11-12 ゼリア新薬工業株式会社 Ophthalmic agent
JP6009141B2 (en) * 2009-10-09 2016-10-19 ロート製薬株式会社 Aqueous composition
JP5992293B2 (en) * 2012-10-31 2016-09-14 大正製薬株式会社 Ophthalmic agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184013A (en) * 1984-03-01 1985-09-19 Yoshitomi Pharmaceut Ind Ltd eye drops
JPH05186349A (en) * 1991-12-30 1993-07-27 Teika Seiyaku Kk Pranoprofen eye drop agent composition
JP3170619B2 (en) * 1995-04-20 2001-05-28 参天製薬株式会社 Planoprofen ophthalmic solution containing organic amine
JPH10236951A (en) * 1996-12-27 1998-09-08 Teika Seiyaku Kk Eye drop containing pranoprofen formulated therein
JPH10295777A (en) * 1997-04-28 1998-11-10 Taisho Pharmaceut Co Ltd Stable antibacterial eye drops

Also Published As

Publication number Publication date
KR100776579B1 (en) 2007-11-15
EP1283042A1 (en) 2003-02-12
WO2001087303A1 (en) 2001-11-22
DE60136064D1 (en) 2008-11-20
CN1210028C (en) 2005-07-13
JP4754149B2 (en) 2011-08-24
PT1283042E (en) 2008-11-19
EP1283042A4 (en) 2007-05-23
EP1283042B1 (en) 2008-10-08
ATE410164T1 (en) 2008-10-15
ES2310550T3 (en) 2009-01-16
KR20020094052A (en) 2002-12-16
CN1438887A (en) 2003-08-27

Similar Documents

Publication Publication Date Title
NO2025027I1 (en) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - extended.
NO20034149L (en) Medicines containing triazaspiro [5.5] undecane derivatives as the active ingredient
MXPA05008909A (en) Intranasal formulation of rotigotine.
ATE332692T1 (en) AQUEOUS LIQUID PREPARATIONS
NO20031273L (en) Substituted cinnamic acid guanidines, process for their preparation, their use as drug and drug containing the same
AU1344102A (en) Reduced-viscosity concentrated protein formulations
MXPA03007712A (en) Pharmaceutical salts.
AU2002350592A1 (en) Ph-sensitive polymer
DK0909562T3 (en) Injection preparation containing a lipid A analog and process for its preparation
PL1683526T3 (en) Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac
MXPA03008630A (en) Arylisoxazoline derivatives, method for production and use thereof as pesticides.
TR200100895T2 (en) Heterocyclic substituted propanolamine derivatives, production, drugs, use
DK1453810T3 (en) Substituted 4-phenyltetrahydroisoquinolines, process for their preparation, their use as a drug containing the same
WO2002053519A3 (en) Hydrophobic polyamine analogs and methods for their use
WO2002100914A3 (en) Polymeric material, containing a latent acid
AU2001258754A1 (en) Aqueous liquid preparation
WO2003024933A1 (en) 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
BR0112258A (en) Poorly Water Soluble Drug Delivery System
AU2001234107A1 (en) Benzoic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
DK1118610T3 (en) Benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing the derivatives
ZA200304928B (en) Medicament containing a polyamine as an active substance.
EA200101150A1 (en) PRUNCTIONAL SOLUTION FOR ORAL APPLICATION
AU2001285944A1 (en) Fungicidal agent containing n-chlorotaurine and use thereof
AU2002328285A1 (en) Method for producing an essentially chlorite-free, stable, aqueous chlorine-oxygen solution, the chlorine-oxygen solution obtained by means of said method, and the use of the same
SE9902742D0 (en) New pharmaceutical formultion